AQR Capital Management LLC Cuts Stock Holdings in Hologic, Inc. (NASDAQ:HOLX)

AQR Capital Management LLC trimmed its holdings in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 11.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 460,298 shares of the medical equipment provider's stock after selling 59,637 shares during the quarter. AQR Capital Management LLC owned approximately 0.21% of Hologic worth $33,183,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. General Partner Inc. acquired a new position in Hologic in the fourth quarter valued at $26,000. Venturi Wealth Management LLC grew its holdings in shares of Hologic by 156.3% during the 4th quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider's stock worth $31,000 after purchasing an additional 261 shares during the period. EverSource Wealth Advisors LLC lifted its position in Hologic by 79.8% during the fourth quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider's stock valued at $42,000 after buying an additional 260 shares in the last quarter. Smartleaf Asset Management LLC lifted its holdings in shares of Hologic by 36.9% during the 4th quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider's stock valued at $43,000 after acquiring an additional 159 shares in the last quarter. Finally, Smithfield Trust Co raised its position in Hologic by 160.0% in the fourth quarter. Smithfield Trust Co now owns 650 shares of the medical equipment provider's stock valued at $45,000 after purchasing an additional 400 shares during the period. 94.73% of the stock is owned by hedge funds and other institutional investors.

Hologic Trading Up 0.3 %

Hologic stock traded up $0.18 during trading hours on Thursday, reaching $55.61. 1,332,908 shares of the company's stock were exchanged, compared to its average volume of 2,066,145. The company has a quick ratio of 2.78, a current ratio of 3.49 and a debt-to-equity ratio of 0.52. Hologic, Inc. has a twelve month low of $51.90 and a twelve month high of $84.67. The firm's 50 day simple moving average is $59.69 and its 200 day simple moving average is $68.69. The firm has a market capitalization of $12.48 billion, a PE ratio of 17.52, a PEG ratio of 2.14 and a beta of 0.54.

Hologic (NASDAQ:HOLX - Get Free Report) last announced its earnings results on Thursday, May 1st. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.02 by $0.01. The firm had revenue of $1.01 billion during the quarter, compared to analyst estimates of $1 billion. Hologic had a return on equity of 19.72% and a net margin of 18.42%. The business's revenue was down 1.2% compared to the same quarter last year. During the same period last year, the firm posted $1.03 EPS. Research analysts predict that Hologic, Inc. will post 4.28 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on HOLX. Raymond James reissued an "outperform" rating and set a $71.00 target price (down from $90.00) on shares of Hologic in a research report on Friday, May 2nd. Leerink Partnrs downgraded Hologic from a "strong-buy" rating to a "hold" rating in a report on Thursday, February 6th. Argus lowered Hologic from a "buy" rating to a "hold" rating in a report on Monday, March 3rd. Morgan Stanley dropped their target price on shares of Hologic from $77.00 to $65.00 and set an "equal weight" rating on the stock in a research report on Monday. Finally, Citigroup reduced their price target on shares of Hologic from $80.00 to $70.00 and set a "neutral" rating for the company in a research report on Tuesday, March 4th. Twelve research analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Hologic currently has a consensus rating of "Hold" and an average target price of $79.85.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.